Compare Gilead Sciences, Inc. (GILD) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Innodata Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Innodata Inc trades at $62.04 (market cap $2.10B). The key difference: Gilead Sciences, Inc. is far larger — about 86.9× Innodata Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Innodata Inc for 19 Days on average.
| GILD | INOD | |
|---|---|---|
Market Cap | $182.40B | $2.10B |
Volume | 4,469,821 | 989,493 |
Sector | Health | Technology |
52-Week High | $155.80 | $121.50 |
52-Week Low | $116.74 | $34.45 |
Typical Hold Time | 111 Days | 19 Days |
Enterprise Value | $205.46B | $1.86B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
INOD trades at $62.04, down 2.17% today, amid a bearish technical signal from moving averages. The company shows strong fundamentals with recent earnings beats, including Q2 2026 EPS of $0.41 versus $0.213 expected, and robust profitability with a 14.66% net income margin. Positive news highlights expansion into motion-capture AI labs and strategic board appointments, supporting growth in AI data services.
Outlook remains positive given earnings momentum and AI sector tailwinds, but risks include high valuation multiples like a P/E of 47.43 and customer concentration. Analyst consensus is bullish with 4 buy ratings, suggesting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
